

NEWS RELEASE**Teijin Nakashima Medical to Acquire
Otsuka Group Company's Spine and Trauma Business**


Tokyo, Japan, October 29, 2021 --- [Teijin Nakashima Medical Co., Ltd.](#), a [Teijin Group](#) company that develops, manufactures and distributes artificial joints, spinal devices and trauma devices, announced today that it has agreed to acquire and take over the spine and trauma (fracture) business of [KiSCO Co., Ltd.](#), owned by [Otsuka Group's Otsuka Medical Devices Co., Ltd.](#) Teijin Nakashima Medical will assume spine and trauma (fracture) business of KiSCO on the 1st day of February 2022.

KiSCO's proprietary products include expandable interbody fusion PEEK cage, a spine-fusion cage system, and a posterior support plate for fixing posterolateral bone fragments. The company also has highly skilled human resources specializing in orthopedics.

Teijin Nakashima Medical, supported by the addition of KiSCO's specialty personnel and products, will target sales of JPY 10 billion by 2025, with a focus on the increasing demand for orthopedic implants in today's aging societies. In particular, Teijin Nakashima Medical expects to grow sales at a rate that exceeds the pace of the implantable medical device market's expansion, and also to strengthen its research and development capabilities.



Expandable interbody fusion
PEEK cage



posterior support plate for fixing
posterolateral bone fragments

About KiSCO Co., Ltd.

Company name	KiSCO Co., Ltd.
Headquarters	Chuo-ku, Kobe-shi, Hyogo Prefecture
Establishment	September 14, 1968
Capital	JPY 1,932.06 million
President	Representative Director Ayumu Nakaji
Employees	91 (as of April 1, 2021)
Business	Developing, manufacturing, import and sales of medical device

KiSCO has been developing and selling implant products such as spinal fixation materials and osteosynthesis materials as a subsidiary of Otsuka Medical Device since 2011.

Teijin has been steadily expanding its commercial involvement with implantable medical devices. Teijin Nakashima Medical joined the Teijin group through a capital tie-up with Nakashima Holdings in 2015. In 2018, Teijin Nakashima Medical acquired the spine business of [Century Medical, Inc.](#), an importer and distributor of medical devices. Teijin also established Teijin Medical Technologies to develop and distribute absorbent bone-connecting material.

Teijin's healthcare business supports people in all stages of life. Through its growing business with implantable medical devices, Teijin look forward to increasingly enhancing the quality of life for people worldwide.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions," Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD 9.5 billion) in the fiscal year that ended on March 31, 2021.

Press Contact

Corporate Communications

Teijin Limited

pr@teijin.co.jp